Piramal Pharma saw an upswing in its share prices during the market open on April 19 following the US Food and Drug Administration’s (USFDA) completion of its inspection of the company’s Sellersville manufacturing facility in the US. During the inspection, which took place between December 19, 2022, and January 13, 2023, the USFDA released an Establishment Inspection Report (EIR), determining the classification of the facility. While this positive outcome indicates that the facility is on track to launch its various forms of medications – such as solid oral dosage forms, liquids, creams and ointments – further regulatory approval from the USFDA may be before commercialization. These findings thus highlight the potential financial impact of delays in regulatory approval for domestic pharma companies.